Literature DB >> 18584264

Sacral chordoma: can local recurrence after sacrectomy be predicted?

S A Hanna1, W J S Aston, T W R Briggs, S R Cannon, A Saifuddin.   

Abstract

UNLABELLED: Surgical resection margins are reportedly the most important predictor of survival and local recurrence with sacral chordomas. We examined the relevance of invasion of the surrounding posterior pelvic musculature (piriformis and gluteus maximus) at initial diagnosis to local recurrence after sacrectomy. We retrospectively reviewed 18 patients with histologically verified sacral chordoma seen at our institution between 1998 and 2005. There were 14 men and four women with a mean age of 65.1 years (range, 31-78 years). The average overall followup was 4.4 years (range, 0.5-10 years), 5.4 years for the living patients (range, 3-10 years), and 2.8 years for the deceased (range, 0.5-5.4 years). Local recurrence occurred in 12 patients (66%) 29 months postoperatively (range, 2-84 months). Six of these patients had wide excisions at initial surgery, five had marginal excisions, and one had an intralesional excision. Ten patients had wide surgical margins, six of whom (60%) had local recurrences. Tumor invasion of adjacent muscles at presentation was present in 14 patients, 12 of whom (85%) had local recurrences. Sacroiliac joint involvement was seen in 10 patients, nine of whom (90%) had local recurrences. The findings suggest obtaining wide surgical margins posteriorly, by excising parts of the piriformis, gluteus maximus, and sacroiliac joints, may result in better local disease control in patients with sacral chordoma. LEVEL OF EVIDENCE: Level IV, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

Entities:  

Mesh:

Year:  2008        PMID: 18584264      PMCID: PMC2493011          DOI: 10.1007/s11999-008-0356-7

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  31 in total

1.  Pelvic strength after major amputation of the sacrum. An exerimental study.

Authors:  B Gunterberg; B Romanus; B Stener
Journal:  Acta Orthop Scand       Date:  1976-12

2.  Chordoma: review of clinicoradiological features and factors affecting survival.

Authors:  M Y Soo
Journal:  Australas Radiol       Date:  2001-11

3.  Chordoma: natural history and results in 28 patients treated at a single institution.

Authors:  D Baratti; A Gronchi; E Pennacchioli; L Lozza; M Colecchia; M Fiore; M Santinami
Journal:  Ann Surg Oncol       Date:  2003-04       Impact factor: 5.344

4.  Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.

Authors:  P Bergh; L G Kindblom; B Gunterberg; F Remotti; W Ryd; J M Meis-Kindblom
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

5.  Local recurrence after S2-3 sacrectomy in sacral chordoma. Report of four cases.

Authors:  Ken Ishii; Kazuhiro Chiba; Masahiko Watanabe; Hiroo Yabe; Yoshikazu Fujimura; Yoshiaki Toyama
Journal:  J Neurosurg       Date:  2002-07       Impact factor: 5.115

6.  Chordoma: an analysis of twenty cases treated over a twenty-year span.

Authors:  I M Ariel; C Verdu
Journal:  J Surg Oncol       Date:  1975       Impact factor: 3.454

7.  A system for the surgical staging of musculoskeletal sarcoma.

Authors:  W F Enneking; S S Spanier; M A Goodman
Journal:  Clin Orthop Relat Res       Date:  1980 Nov-Dec       Impact factor: 4.176

8.  Imatinib mesylate in chordoma.

Authors:  Paolo G Casali; Antonella Messina; Silvia Stacchiotti; Elena Tamborini; Flavio Crippa; Alessandro Gronchi; Rosaria Orlandi; Carla Ripamonti; Carlo Spreafico; Raffaello Bertieri; Rossella Bertulli; Maurizio Colecchia; Elena Fumagalli; Angela Greco; Federica Grosso; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  Cancer       Date:  2004-11-01       Impact factor: 6.860

9.  Chordoma. A clinicopathologic and prognostic study of a Swedish national series.

Authors:  B Eriksson; B Gunterberg; L G Kindblom
Journal:  Acta Orthop Scand       Date:  1981-02

Review 10.  Chordoma.

Authors:  Paolo G Casali; Silvia Stacchiotti; Claudia Sangalli; Patrizia Olmi; Alessandro Gronchi
Journal:  Curr Opin Oncol       Date:  2007-07       Impact factor: 3.645

View more
  38 in total

1.  High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis.

Authors:  Kai Zhang; Hao Chen; Guizhong Wu; Kangwu Chen; Huilin Yang
Journal:  Med Oncol       Date:  2014-09-27       Impact factor: 3.064

2.  Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma.

Authors:  Matthew T Houdek; Peter S Rose; Mario Hevesi; Joseph H Schwab; Anthony M Griffin; John H Healey; Ivy A Petersen; Thomas F DeLaney; Peter W Chung; Michael J Yaszemski; Jay S Wunder; Francis J Hornicek; Patrick J Boland; Franklin H Sim; Peter C Ferguson
Journal:  J Surg Oncol       Date:  2019-02-07       Impact factor: 3.454

3.  Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.

Authors:  Kai Zhang; Hao Chen; Bin Zhang; Jiajia Sun; Jian Lu; Kangwu Chen; Huilin Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

4.  Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.

Authors:  Reza Akhavan-Sigari; Michael Robert Gaab; Veit Rohde; Mehdi Abili; Helmut Ostertag
Journal:  Eur Spine J       Date:  2014-06-15       Impact factor: 3.134

5.  Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival.

Authors:  Péter Pál Varga; Zsolt Szövérfi; Charles G Fisher; Stefano Boriani; Ziya L Gokaslan; Mark B Dekutoski; Dean Chou; Nasir A Quraishi; Jeremy J Reynolds; Alessandro Luzzati; Richard Williams; Michael G Fehlings; Niccole M Germscheid; Aron Lazary; Laurence D Rhines
Journal:  Eur Spine J       Date:  2014-12-23       Impact factor: 3.134

6.  [18F]-Fluoromisonidazole positron emission tomography/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine.

Authors:  Matthew D Cheney; Yen-Lin Chen; Ruth Lim; Barbara K Winrich; Anca L Grosu; Alexei V Trofimov; Nicolas Depauw; Helen A Shih; Joseph H Schwab; Francis J Hornicek; Thomas F DeLaney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-01       Impact factor: 7.038

7.  Image-guided percutaneous lipiodol-pingyangmycin suspension injection therapy for sacral chordoma.

Authors:  Dexiao Huang; Yong Chen; Qingle Zeng; Renhua Wu; Yanhao Li
Journal:  Korean J Radiol       Date:  2013-08-30       Impact factor: 3.500

8.  Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.

Authors:  Yongkun Yang; Xiaohui Niu; Yuan Li; Weifeng Liu; Hairong Xu
Journal:  Eur Spine J       Date:  2016-12-09       Impact factor: 3.134

Review 9.  Cryosurgery in the excision of a giant local recurrent sacral chordoma: a case report and literature review.

Authors:  Valerio Pipola; Marco Girolami; Riccardo Ghermandi; Giuseppe Tedesco; Gisberto Evangelisti; Alessandro Gasbarrini
Journal:  Eur Spine J       Date:  2018-01-25       Impact factor: 3.134

10.  What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?

Authors:  Tao Ji; Wei Guo; Rongli Yang; Xiaodong Tang; Yifei Wang; Lin Huang
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.